A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations

Hongguang Li; Chen Xie; Rongfeng Lan; Shuai Zha; Chi-Fai Chan; Wing-Yan Wong; Ka-Lok Ho; Brandon Dow Chan; Yuxia Luo; Jing-Xiang Zhang; Ga-Lai Law; William C. S. Tai; Jean-Claude G. Bünzli; Ka-Leung Wong

doi:10.1021/acs.jmedchem.7b01162

A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations

Hongguang Li
, Chen Xie
, Rongfeng Lan
, Shuai Zha
, Chi-Fai Chan
, Wing-Yan Wong
, Ka-Lok Ho
, Brandon Dow Chan
, Yuxia Luo
, Jing-Xiang Zhang
, Ga-Lai Law
, William C. S. Tai
, Jean-Claude G. Bünzli
, Ka-Leung Wong

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

56 Citations (Scopus)

Abstract

A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λ_irr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs. © 2017 American Chemical Society.

Original language	English
Pages (from-to)	8923-8932
Journal	Journal of Medicinal Chemistry
Volume	60
Issue number	21
DOIs	https://doi.org/10.1021/acs.jmedchem.7b01162
Publication status	Published - 9 Nov 2017
Externally published	Yes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

Funding

This work was funded by grants from The Hong Kong Research Grants Council (HKBU 12309516), HKBU (FRG 2/ 16-17/016), and National Natural Science Foundation of China (21402167 and 21401035), Natural Science Foundation of Guangdong Province (2014A030307027), and Dr Kennedy Y. H. Wong Distinguished Visiting Professorship Scheme 2016/ 17, Hong Kong Baptist University (J.C.G.B.).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

RGC Funding Information

RGC-funded

Access Output

10.1021/acs.jmedchem.7b01162

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

Li, H., Xie, C., Lan, R., Zha, S., Chan, C.-F., Wong, W.-Y., Ho, K.-L., Chan, B. D., Luo, Y., Zhang, J.-X., Law, G.-L., Tai, W. C. S., Bünzli, J.-C. G., & Wong, K.-L. (2017). A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations. Journal of Medicinal Chemistry, 60(21), 8923-8932. https://doi.org/10.1021/acs.jmedchem.7b01162

@article{8ad98d9ffff243f9adbef8ac42e400a3,

title = "A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations",

abstract = "A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λirr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs. {\textcopyright} 2017 American Chemical Society.",

author = "Hongguang Li and Chen Xie and Rongfeng Lan and Shuai Zha and Chi-Fai Chan and Wing-Yan Wong and Ka-Lok Ho and Chan, \{Brandon Dow\} and Yuxia Luo and Jing-Xiang Zhang and Ga-Lai Law and Tai, \{William C. S.\} and B{\"u}nzli, \{Jean-Claude G.\} and Ka-Leung Wong",

note = "Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].",

year = "2017",

month = nov,

day = "9",

doi = "10.1021/acs.jmedchem.7b01162",

language = "English",

volume = "60",

pages = "8923--8932",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "21",

}

Li, H, Xie, C, Lan, R, Zha, S, Chan, C-F, Wong, W-Y, Ho, K-L, Chan, BD, Luo, Y, Zhang, J-X, Law, G-L, Tai, WCS, Bünzli, J-CG & Wong, K-L 2017, 'A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations', Journal of Medicinal Chemistry, vol. 60, no. 21, pp. 8923-8932. https://doi.org/10.1021/acs.jmedchem.7b01162

A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations. / Li, Hongguang; Xie, Chen; Lan, Rongfeng et al.
In: Journal of Medicinal Chemistry, Vol. 60, No. 21, 09.11.2017, p. 8923-8932.

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

TY - JOUR

T1 - A Smart Europium-Ruthenium Complex as Anticancer Prodrug

T2 - Controllable Drug Release and Real-Time Monitoring under Different Light Excitations

AU - Li, Hongguang

AU - Xie, Chen

AU - Lan, Rongfeng

AU - Zha, Shuai

AU - Chan, Chi-Fai

AU - Wong, Wing-Yan

AU - Ho, Ka-Lok

AU - Chan, Brandon Dow

AU - Luo, Yuxia

AU - Zhang, Jing-Xiang

AU - Law, Ga-Lai

AU - Tai, William C. S.

AU - Bünzli, Jean-Claude G.

AU - Wong, Ka-Leung

N1 - Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

PY - 2017/11/9

Y1 - 2017/11/9

N2 - A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λirr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs. © 2017 American Chemical Society.

AB - A unique, dual-function, photoactivatable anticancer prodrug, RuEuL, has been tailored that features a ruthenium(II) complex linked to a cyclen-europium chelate via a π-conjugated bridge. Under irradiation at 488 nm, the dark-inactive prodrug undergoes photodissociation, releasing the DNA-damaging ruthenium species. Under evaluation-window irradiation (λirr = one-photon 350 nm or two-photon 700 nm), the drug delivery process can be quantitatively monitored in real-time because of the long-lived red europium emission. Linear relationships between released drug concentration and ESI-MS or luminescence responses are established. Finally, the efficiency of the new prodrug is demonstrated both in vitro RuEuL anticancer prodrug over some existing ones and open the way for decisive improvements in multipurpose prodrugs. © 2017 American Chemical Society.

UR - https://www.scopus.com/pages/publications/85033408940

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85033408940&origin=recordpage

U2 - 10.1021/acs.jmedchem.7b01162

DO - 10.1021/acs.jmedchem.7b01162

M3 - RGC 21 - Publication in refereed journal

C2 - 28991460

SN - 0022-2623

VL - 60

SP - 8923

EP - 8932

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 21

ER -

A Smart Europium-Ruthenium Complex as Anticancer Prodrug: Controllable Drug Release and Real-Time Monitoring under Different Light Excitations

Abstract

Bibliographical note

Funding

UN SDGs

RGC Funding Information

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this